Barclays PLC Mei Pharma, Inc. Transaction History

Barclays PLC

  • $327 Billion
  • Q2 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022
SELL
$0.41 - $8.8 $17,951 - $385,290
-43,783 Reduced 90.0%
4,865 $2,000
Q2 2022

Aug 12, 2022
SELL
$0.42 - $0.65 $8,927 - $13,816
-21,256 Reduced 30.41%
48,648 $29,000
Q1 2022

May 16, 2022
SELL
$0.54 - $2.74 $33,308 - $169,011
-61,683 Reduced 46.88%
69,904 $42,000
Q4 2021

Feb 14, 2022
BUY
$2.33 - $3.37 $203,369 - $294,143
87,283 Added 197.01%
131,587 $351,000
Q3 2021

Nov 09, 2021
BUY
$2.52 - $2.99 $75,090 - $89,096
29,798 Added 205.42%
44,304 $122,000
Q2 2021

Aug 13, 2021
SELL
$2.6 - $3.65 $279,195 - $391,947
-107,383 Reduced 88.1%
14,506 $41,000
Q1 2021

May 13, 2021
BUY
$2.73 - $4.5 $153,666 - $253,296
56,288 Added 85.8%
121,889 $418,000
Q4 2020

Feb 11, 2021
SELL
$2.6 - $3.32 $30,685 - $39,182
-11,802 Reduced 15.25%
65,601 $173,000
Q3 2020

Nov 12, 2020
SELL
$2.46 - $4.27 $23,839 - $41,380
-9,691 Reduced 11.13%
77,403 $241,000
Q2 2020

Aug 12, 2020
BUY
$1.45 - $4.3 $43,903 - $130,195
30,278 Added 53.29%
87,094 $359,000
Q1 2020

May 13, 2020
SELL
$0.75 - $2.55 $28,436 - $96,683
-37,915 Reduced 40.02%
56,816 $92,000
Q4 2019

Feb 10, 2020
BUY
$1.65 - $2.48 $60,710 - $91,249
36,794 Added 63.51%
94,731 $235,000
Q3 2019

Nov 14, 2019
SELL
$1.48 - $2.52 $18,340 - $31,227
-12,392 Reduced 17.62%
57,937 $97,000
Q2 2019

Aug 14, 2019
SELL
$2.45 - $3.32 $665,993 - $902,488
-271,834 Reduced 79.45%
70,329 $176,000
Q1 2019

May 15, 2019
BUY
$2.52 - $3.24 $263,483 - $338,764
104,557 Added 44.0%
342,163 $1.05 Million
Q4 2018

Feb 14, 2019
BUY
$1.92 - $4.1 $408,587 - $872,504
212,806 Added 858.09%
237,606 $627,000
Q3 2018

Nov 14, 2018
BUY
$3.39 - $4.61 $84,072 - $114,328
24,800 New
24,800 $107,000

Others Institutions Holding MEIP

# of Institutions
1
Shares Held
2K
Call Options Held
0
Put Options Held
0
View Full List

About MEI Pharma, Inc.

MEIP Quotes by TradingView
  • Ticker MEIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 133,261,000
  • Market Cap $370M
  • Description
  • MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...
More about MEIP
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email